| ID | 1151 |
| Name of the vaccine | PedvaxHib |
| Microbe | Bacteria |
| Disease name | Haemophilus influenzae type b (Hib) |
| Name of bacteria | Haemophilus influenzae |
| Type of vaccine | Conjugate |
| Nucleic acid content | DNA |
| Age | 2 to 71 months |
| Description of the vaccine | Haemophilus b Conjugate Vaccine (Meningococcal Protein Conjugate) (PRP-OMPC). |
| Name of the manufacturer | Merck and Co. , INC. |
| Name of the manufacturing country | United States |
| Year of manufacture | 1989 |
| Clinical Phase status | Approved |
| Bacterial strain | Anaerobic gram-negative coccobacillus. |
| Efficacy | 93% for primary two doses. Efficacy for follow up period - 96.6% in children under 18 months and 100% in children over 18 months of age. |
| Vaccine formulation | Liquid |
| Dosage | Infants (2 to 14 months) : 0.5 mL dose at 2 months and a dose 2 months later. A booster dose (0.5 mL) at 12 to 15 months.
Children (15 months and older) : single 0.5 mL dose. |
| Mechanism of action | From 0.15 to 1.0 mcg/mL. |
| Route of administration | Intramuscular |
| Indications | Routine vaccination against invasive disease caused by Haemophilus influenzae type b. |
| Export | Distributed by - Merck and Co. , INC. |
| Approval | NA |
| Adjuvant | NA |
| Repurposing | For Meningococcal disease. |
| Side effects of vaccine | Irritability, sleepiness, injection site pain, erythema, swelling, unusual high pitched crying, prolonged crying, diarrhoea, vomiting, otitis media, rash, and upper respiratory infection. |
| Post vaccination | NA |
| Dose type | Both |
| Interspecies transfer | NA |
| PubMed identifier | NA |
| Clinical trial number | NA |
| Reference | https://www.fda.gov/media/80438/download |
| Other name | NA |
| Additional Links | NA
|